$RNAZ Cashflow Statement | Understand Stock

$RNAZ

$1.67 -$0.04 (2.08%) Close

$RNAZ Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Amortization of right-of-use asset
Non-cash transaction costs
Share-based compensation expense
Loss on sale of equipment
Change in fair value of derivative liabilities
Change in fair market value of derivative liabilities
Non-cash interest expense
Change in fair value of contingent consideration
Change in fair value of warrant liabilities
Due to related parties
PIPE warrant issuance cost
Due from related parties
Changes in assets and liabilities:
Prepaid expenses and other current assets
Accounts payable and accrued expenses
Deferred grant income
Grants receivable
Payment of amount due to related parties
Accrued interest on convertible promissory notes
Security deposit
Operating lease liability
Deferred Tax Liability
Net cash used in operating activities

Cash flows from investing activities:
Cash acquired through the acquisition of Polynoma
Purchase of equipment
Proceeds from sale of equipment
Net cash used in investing activities

Cash flows from financing activities:
Proceeds from initial public offering (IPO) of common stock, net of offering costs
Proceeds from escrow for warrant exercise advances
Proceeds from offering of preferred stock (Series B), net of offering costs
Net proceeds from sales of common stock
Proceeds from exercise of stock options
Proceeds from subscription receivable
Proceeds from exercise of warrants
Payments of deferred offering costs
Net cash provided by financing activities

Net change in cash
Cash, beginning of year
Cash, end of year
Cash paid during the period for:
Interest related to insurance premium payment plan
Supplemental disclosure of non-cash investing and financing activities:
Accrued interest on subscriptions receivable
Conversion of convertible promissory notes, including embedded derivative, to common stock
Deferred offering costs adjusted into additional paid-in capital in connection with IPO
Fair value of warrant liability associated with warrant exercise
Underwriting discounts and commissions paid from gross proceeds of IPO
Right-of-use assets obtained in exchange for operating lease liabilities
Deemed dividend arising from warrant modification
Recognition of liability
Series C warrants
Series D warrants
Exercise of Series D warrants
Accrual of paid-in-kind dividends on Series A Non-Voting Convertible Preferred Stock
Preferred stock issued in connection with acquisition of Polynoma
Common stock issued in connection with acquisition of Polynoma

Comments